SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 22, 2001
----------------
SALIX PHARMACEUTICALS, LTD.
----------------------------------------------------------
(Exact name of registrant as specified in its charter)
British Virgin Islands
- -------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
000-23265 94-3267443
- ---------------------------------- -------------------------------
(Commission file Number) (IRS Employer ID Number)
3801 Wake Forest Road, Raleigh, North Carolina 27609
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 862-1000
----------------------------
Item 5. Other Events and Regulation FD Disclosure.
On January 22, 2001, Salix Pharmaceuticals, Ltd. ("Salix") announced the
launch of its first product, COLAZAL(TM).
On February 13, 2001, Salix announced its operating results for the quarter
and year ended December 31, 2000.
On February 26, 2001, Salix announced that its shares of common stock began
trading on the Nasdaq National Market.
Copies of these press releases are attached as exhibits.
Item 7. Financial Statements and Exhibits
(c) Exhibits
99.1 Press Release dated January 22, 2001
99.2 Press Release dated February 13, 2001
99.3 Press Release dated February 26, 2001
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SALIX PHARMACEUTICALS, LTD.
Date: February 27, 2001 By: /s/ Adam C. Derbyshire
-------------------------------------
Adam C. Derbyshire
Vice President and Chief Financial
Officer